Articles By Mrinalini Dey, MD

safety data

Upadacitinib: revisiting safety data in RA and GCA

By Mrinalini Dey, MD

For the last several years, conversations about JAK inhibitors have often started and ended with safety. The shadow cast by ORAL Surveillance has made clinicians more cautious and regulators more restrictive.

Read Article
microbiome,blue

Microbiome may hold key to methotrexate response in RA

By Mrinalini Dey, MD

Methotrexate (MTX) remains the cornerstone of rheumatoid arthritis (RA) treatment, yet it remains unclear as to how to predict who will respond to it. Two studies presented at ACR (Abstracts 2639 and 2643) suggest the answer may be hiding in the gut.

Read Article
GLP-1.pink

GLP-1 Receptor Agonists: Impacts Beyond Metabolism?

By Mrinalini Dey, MD

The GLP-1 story has been hard to miss this year, and at ACR Convergence, it’s clear that these drugs are starting to make real waves in rheumatology. Across multiple abstracts, investigators have used a large real-world dataset, the TriNetX network, to explore how GLP-1 receptor agonists (GLP-1RAs) might influence cardiovascular, renal and immune-mediated outcomes in our patients.

Read Article
Fitbit

From Fitbit to first diagnosis: AI is rewriting the RA playbook

By Mrinalini Dey, MD

Artificial intelligence isn’t a distant frontier anymore. It’s here, and it appears able to detect signs of rheumatoid arthritis, possibly before we can clinically detect it. Two studies presented at this year’s ACR meeting highlight just how close we may be to a future where algorithms flag disease before we can and monitor activity with minimal patient burden.

Read Article
Puzzle pieces

ICYMI: Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD

By Mrinalini Dey, MD

Connective tissue diseases (CTDs) and interstitial lung disease (ILD) represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment. Research presented at EULAR 2025 continues to highlight the importance of CTD-ILD and the evolving landscape of therapeutic options for patients with autoimmune ILDs.

Read Article
puzzle.RA_.jpg

Persistent Burden in Early RA Despite Disease Control: insights from CareRA Trials

By Mrinalini Dey, MD

Advances in the treatment of rheumatoid arthritis, particularly the treat-to-target strategy and the introduction of effective DMARDs, have improved the management of inflammation in RA. However, improved inflammatory markers do not always translate into a resolution of patients’ symptoms or improvements in functional capacity. A recent pooled analysis from the CareRA and CareRA2020 randomized controlled trials shed new light on this dissociation between biological disease control and patient-reported outcomes.

Read Article
Puzzle pieces

Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD

By Mrinalini Dey, MD

Connective tissue diseases (CTDs) and interstitial lung disease (ILD) represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment. Research presented at EULAR 2025 continues to highlight the importance of CTD-ILD and the evolving landscape of therapeutic options for patients with autoimmune ILDs.

Read Article
world globe with a line of people

Health inequities in rheumatology: A central theme

By Mrinalini Dey, MD

This year at EULAR, health inequalities have taken centre stage as fundamental drivers of outcomes in rheumatic and musculoskeletal diseases. Across multiple sessions and studies, delegates are presenting compelling evidence and ground-breaking research demonstrating that who you are, where you live, and what resources you can access truly do shape the trajectory of chronic illness just as much as biological factors.

Read Article
GCA,woman

ICYMI: SELECT-GCA suggests JAKis may be the new kid on the block

By Mrinalini Dey, MD

Clinicians treating giant cell arteritis (GCA) have long had to contend with a disappointingly limited selection of drugs from which to select. A new group of drugs is finally showing promise in the treatment of GCA.

Read Article
heart,CV,MI.cardia,

Addressing CV Risk in RA: Are we doing enough?

By Mrinalini Dey, MD

ORAL surveillance was a post-authorisation safety study of tofacitinib 5mg and 10mg versus TNF inhibitors, focusing on rates of adverse events, including MACE. A higher incidence of MACE was observed with the use of tofacitinib. Statins are recommended in patients with a history of atherosclerotic disease or 10 year predicted risk of MACE. But, how many patients with rheumatoid arthritis, at risk of MACE, are actually taking a statin?

Read Article
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Profile picture for user Mrinalini Dey, MD
  • Mrinalini Dey, MD

  • Dr. Mrinalini Dey is a Clinical Research Fellow at the Centre for Rheumatic Diseases, King’s College London, UK. She is also a Fellow-In-Training in Rheumatology and General Internal Medicine.  She is currently pursuing a clinical PhD examining the role comorbidities and social determinants of health in outcomes in inflammatory arthritis.

    Since graduating from the University of Cambridge, in 2016, Mrinalini has pursued a clinical research career focussing on epidemiology, mixed-methods research and outcomes in inflammatory arthritis. Mrinalini sits on the Editorial Board and Digital and Social Media Committee for Rheumatology journal. She the Co-Chair of the Social Media Subcommittee of the Emerging EULAR Network (EMEUNET), as well as sitting on the EULAR People with Arthritis and Rheumatism in Europe (PARE) and Advocacy Committees. Mrinalini has a passion for teaching and science communication, and has previously been a reporter for RheumNow, as well as EULAR TV.

×